HTG Molecular Diagnostics (HTGMQ) 10-Q 8 Aug 17 2017 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2017	Aug. 04, 2017
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	Q2
Trading Symbol	HTGM
Entity Registrant Name	HTG Molecular Diagnostics, Inc
Entity Central Index Key	1,169,987
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		11,448,443

Condensed Balance Sheets

Condensed Balance Sheets - USD ($)	Jun. 30, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 13,398,036	$ 7,507,659
Short-term investments available-for-sale, at fair value		4,304,901
Accounts receivable	1,550,868	1,377,441
Inventory, net of allowance of $207,880 at June 30, 2017 and $270,307 at December 31, 2016	1,313,507	1,511,053
Prepaid expenses and other	468,431	433,328
Total current assets	16,730,842	15,134,382
Deferred offering costs		49,630
Property and equipment, net	2,880,487	3,270,197
Total assets	19,611,329	18,454,209
Current liabilities:
Accounts payable	1,343,912	761,663
Accrued liabilities	1,213,611	1,670,286
Deferred revenue - current	637,929	335,659
NuvoGen obligation - current	509,618	604,751
Term loan payable - current	6,668,789	6,389,782
Other current liabilities	224,875	258,850
Total current liabilities	10,598,734	10,020,991
Term loan payable - non-current, net of discount and debt issuance costs	2,214,820	5,389,137
NuvoGen obligation - non-current, net of discount	7,811,866	8,017,356
Other non-current liabilities	533,806	619,587
Total liabilities	21,159,226	24,047,071
Commitments and Contingencies
Stockholders’ deficit:
Common stock, $0.001 par value; 200,000,000 shares authorized at June 30, 2017 and December 31, 2016; 11,358,324 shares issued and outstanding, at June 30, 2017; 7,939,967 and 7,938,571 shares issued and outstanding, respectively, at December 31, 2016	11,357	7,938
Additional paid-in-capital	125,703,966	110,081,334
Treasury stock, no shares as of June 30, 2017 and 1,396 shares as of December 31, 2016		(75,000)
Accumulated other comprehensive loss		(1,090)
Accumulated deficit	(127,263,220)	(115,606,044)
Total stockholders’ deficit	(1,547,897)	(5,592,862)
Total liabilities and stockholders' deficit	$ 19,611,329	$ 18,454,209

Condensed Balance Sheets (Paren

Condensed Balance Sheets (Parenthetical) - USD ($)	Jun. 30, 2017	Dec. 31, 2016
Statement Of Financial Position [Abstract]
Inventory net allowance	$ 207,880	$ 270,307
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	11,358,324	7,939,967
Common stock, shares outstanding	11,358,324	7,938,571
Treasury stock, shares	0	1,396

Condensed Statements of Operati

Condensed Statements of Operations - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Revenue:
Product	$ 407,177	$ 577,127	$ 948,321	$ 1,177,317
Service	1,353,579	1,318,689	2,183,604	1,583,731
Total revenue	1,760,756	1,895,816	3,131,925	2,761,048
Cost of revenue	1,236,904	932,976	2,532,206	1,776,446
Gross margin	523,852	962,840	599,719	984,602
Operating expenses:
Selling, general and administrative	4,413,437	4,712,637	8,651,904	9,406,345
Research and development	1,618,889	2,611,591	2,885,952	4,605,692
Total operating expenses	6,032,326	7,324,228	11,537,856	14,012,037
Operating loss	(5,508,474)	(6,361,388)	(10,938,137)	(13,027,435)
Other income (expense):
Interest expense	(350,058)	(538,889)	(748,478)	(931,346)
Interest income	17,622	31,092	29,711	66,571
Total other income (expense)	(332,428)	(489,355)	(718,759)	(846,333)
Other income	8	18,442	8	18,442
Net loss before income taxes	(5,840,902)	(6,850,743)	(11,656,896)	(13,873,768)
Provision for income taxes		860	280	4,259
Net loss	$ (5,840,902)	$ (6,851,603)	$ (11,657,176)	$ (13,878,027)
Net loss per share, basic and diluted	$ (0.60)	$ (0.98)	$ (1.31)	$ (2)
Shares used in computing net loss per share, basic and diluted	9,769,322	7,018,502	8,875,177	6,952,012

Condensed Statements of Compreh

Condensed Statements of Comprehensive Loss - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Statement Of Income And Comprehensive Income [Abstract]
Net loss	$ (5,840,902)	$ (6,851,603)	$ (11,657,176)	$ (13,878,027)
Other comprehensive income, net of tax effect:
Unrealized gain on short and long-term investments	736	4,522	1,090	43,873
Comprehensive loss	$ (5,840,166)	$ (6,847,081)	$ (11,656,086)	$ (13,834,154)

Condensed Statements of Changes

Condensed Statements of Changes in Stockholders' Deficit - 6 months ended Jun. 30, 2017 - USD ($)	Total	Common Stock	Additional Paid-In Capital	Treasury Stock	Accumulated Other Comprehensive Loss	Accumulated Deficit
Balance at Dec. 31, 2016	$ (5,592,862)	$ 7,938	$ 110,081,334	$ (75,000)	$ (1,090)	$ (115,606,044)
Balance, shares at Dec. 31, 2016		7,938,571
Exercise of stock options	109,786	$ 41	109,745
Exercise of stock options, shares		40,809
Stock-based compensation expense	814,429		814,429
Vesting of restricted stock units	154	$ 154
Vesting of restricted stock units, shares		154,000
Employee stock purchase plan	100,912	$ 40	100,872
Employee stock purchase plan, shares		39,972
Issuance of common stock from the ATM Offering	$ 14,675,770	$ 3,185	14,672,585
Issuance of common stock from the ATM Offering, Shares	3,184,972	3,184,972
Retirement of treasury stock		$ (1)	(74,999)	$ 75,000
Net loss	$ (11,657,176)					(11,657,176)
Unrealized gain on short and long-term investments	1,090				$ 1,090
Balance at Jun. 30, 2017	$ (1,547,897)	$ 11,357	$ 125,703,966			$ (127,263,220)
Balance, shares at Jun. 30, 2017		11,358,324

Condensed Statements of Change7

Condensed Statements of Changes in Stockholders' Deficit (Parenthetical) $ in Millions	6 Months Ended
	Jun. 30, 2017USD ($)
Statement Of Stockholders Equity [Abstract]
At the market offering, issuance costs	$ 0.7

Condensed Statements of Cash Fl

Condensed Statements of Cash Flows - USD ($)	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Operating activities
Net loss	$ (11,657,176)	$ (13,878,027)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	587,466	728,828
Accretion of discount on NuvoGen obligation	99,377	104,467
Provision for excess inventory	244,026	149,763
Amortization of Growth Term Loan discount and issuance costs	231,319	267,047
Stock-based compensation expense	814,583	322,136
Employee stock purchase plan expense	29,223
Accretion of incentive from landlord	(71,000)	(59,165)
Accrued interest on available-for-sale securities investments	5,991	125,138
Changes in operating assets and liabilities:
Accounts receivable	(173,427)	(1,195,148)
Inventory	(19,673)	(161,570)
Prepaid expenses and other	(35,103)	(228,723)
Deferred offering costs	49,630
Accounts payable	480,025	799,786
Accrued liabilities	(456,675)	(42,404)
Deferred revenue	278,310	136,231
Net cash used in operating activities	(9,593,104)	(12,931,641)
Investing activities
Purchase of property and equipment	(152,339)	(1,620,946)
Sales, redemptions and maturities of available-for-sale securities	4,300,000	18,700,000
Purchase of available-for-sale securities		(3,381,271)
Net cash provided by investing activities	4,147,661	13,697,783
Financing activities
Payment of offering costs	(201,475)
Proceeds from Growth Term Loan		5,000,000
Payments on Growth Term Loan	(3,126,629)	(1,450,576)
Proceeds from ATM offering	14,907,245
Payments on capital leases	(24,796)	(66,706)
Proceeds from exercise of stock options	109,786	2,142
Proceeds from shares purchased under the stock purchase plan	71,689	146,758
Payments on NuvoGen obligation	(400,000)	(181,250)
Net cash provided by financing activities	11,335,820	3,450,368
Increase in cash and cash equivalents	5,890,377	4,216,510
Cash and cash equivalents at beginning of period	7,507,659	3,293,983
Cash and cash equivalents at end of period	13,398,036	7,510,493
Noncash investing and financing activities
Fixed asset purchases payable and accrued at period end	72,224	214,033
Offering costs payable at period end	30,000
Carrying value of demonstration units transferred from property and equipment to inventory	26,807
Stock issued for settlement of accrued bonus		(364,910)
Purchase of property and equipment under capital lease		209,588
Incentive from landlord		710,000
Retirement of treasury stock	75,000
Supplemental cash flow information
Cash paid for interest	$ 417,782	$ 559,832

Description of Business

Description of Business	6 Months Ended
	Jun. 30, 2017
Accounting Policies [Abstract]
Description of Business	Note 1. Description of Business HTG Molecular Diagnostics, Inc. (the “Company”) is a commercial stage company that develops and markets products and services based on proprietary technology that facilitates the routine use of targeted molecular profiling. The Company derives revenue from sales of the Company’s automation systems and integrated next-generation sequencing-based HTG EdgeSeq assays and from sample processing, custom research use only assay development, and collaboration services. The Company operates in one segment and the majority of its customers are located in the United States. For the three and six months ended June 30, 2017 approximately 34% and 27%, respectively, of the Company’s revenue was generated from sales to customers located outside of the United States, compared with 10% for both the three and six months ended June 30, 2016.

Basis of Presentation

Basis of Presentation	6 Months Ended
	Jun. 30, 2017
Accounting Policies [Abstract]
Basis of Presentation	Note 2. Basis of Presentation Basis of Presentation The accompanying interim unaudited condensed financial statements have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) and reflect the accounts of the Company as of June 30, 2017 and for the three and six months ended June 30, 2017 and 2016. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles in the United States of America (“GAAP”) for complete financial statements. The accompanying interim unaudited, condensed financial statements reflect all adjustments consisting of normal recurring adjustments which, in the opinion of management, are necessary for a fair statement of the Company’s financial position and the results of its operations and cash flows, as of and for the periods presented. The unaudited condensed balance sheet at December 31, 2016 has been derived from the audited financial statements at that date but does not include all of the information and disclosures required by GAAP for annual financial statements. The results of operations for the interim periods are not necessarily indicative of the results to be expected for the full year. These financial statements should be read in conjunction with the Company’s audited financial statements and notes thereto for the fiscal year ended December 31, 2016, included in the Company’s Annual Report on Form 10-K filed with the SEC on March 23, 2017. Going Concern In accordance with the criteria of Accounting Standards Update (“ASU”) No. 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern The Company will need to raise additional capital to fund its operations until its revenue reaches a level sufficient to provide for self-sustaining cash flows. There can be no assurance that additional capital will be available on acceptable terms, or at all, or that the Company’s revenue will reach a level sufficient to provide for self-sustaining cash flows. If sufficient additional capital is not available as and when needed, the Company may have to delay, scale back or discontinue one or more product development programs, curtail its commercialization activities, significantly reduce expenses, sell assets (potentially at a discount to their fair value or carrying value), enter into relationships with third parties to develop or commercialize products or technologies that the Company otherwise would have sought to develop or commercialize independently, cease operations altogether, pursue a sale of the Company at a price that may result in up to a total loss on investment for its stockholders, file for bankruptcy or seek other protection from creditors, or liquidate all assets. In addition, if the Company defaults under its term loan agreement, its lenders could foreclose on its assets, including substantially all of its cash and cash equivalents which are held in accounts with its lenders. Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. The Company’s significant estimates include revenue recognition, stock-based compensation expense, income tax valuation allowances, recovery of long-lived assets, inventory obsolescence and inventory valuation. Actual results could materially differ from those estimates. Fair Value of Financial Instruments The carrying value of financial instruments classified as current assets and current liabilities approximate fair value due to their liquidity and short-term nature. Investments that are classified as available-for-sale are recorded at fair value, which was determined using quoted market prices, broker or dealer quotations or alterative pricing sources with reasonable levels of transparency. The Growth Term Loan and NuvoGen obligation are considered financial instruments. However, the Company is unable to reasonably determine the fair value of these obligations. Concentration Risks Financial instruments that potentially subject the Company to credit risk consist principally of cash and cash equivalents and uncollateralized accounts receivable. The Company maintains the majority of its cash balances in the form of cash deposits in bank checking and money market accounts in amounts in excess of federally insured limits. Management believes, based upon the quality of the financial institution, that the credit risk with regard to these deposits is not significant. The Company sells its instruments, consumables, sample processing services, custom panel design and development services primarily to biopharmaceutical companies, academic institutions and molecular labs. The Company routinely assesses the financial strength of its customers and credit losses have been minimal to date. The Company had product revenue consisting of revenue from the sale of instruments and consumables for the three and six months ended June 30, 2017 and 2016, as follows: Three Months Ended June 30, Six Months Ended June 30, 2017 2016 2017 2016 Instruments $ 148,479 $ 3,119 $ 171,058 $ 82,300 Consumables 258,698 574,008 777,263 1,095,017 Total product revenue $ 407,177 $ 577,127 $ 948,321 $ 1,177,317 The Company had service revenue consisting of revenue from custom assay development and sample processing for the three and six months ended June 30, 2017 and 2016, as follows: Three Months Ended June 30, Six Months Ended June 30, 2017 2016 2017 2016 Custom assay development $ 582,072 $ — $ 623,359 $ — Sample processing 469,096 1,318,689 1,257,834 1,583,731 Collaboration agreement 302,411 — 302,411 — Total service revenue $ 1,353,579 $ 1,318,689 $ 2,183,604 $ 1,583,731 The Company’s top three customers accounted for 16%, 15% and 13% of the Company’s total revenue for the three months ended June 30, 2017, compared with 60%, 11% and 5% for the three months ended June 30, 2016. The top three customers accounted for 16%, 12% and 9% of the Company’s revenue for the six months ended June 30, 2017, compared with 43%, 18% and 7% for the six months ended June 30, 2016. The top two customers accounted for approximately 13% and 12% of the Company’s accounts receivable as of June 30, 2017, compared with approximately 28% and 15% as of December 31, 2016. The Company currently relies on a single supplier to supply a subcomponent used in the HTG EdgeSeq processors and a second single supplier to provide raw materials used in its HTG EdgeSeq proprietary assays. A loss of either of these suppliers could significantly delay the delivery of products or the completion of services to be performed, which in turn would materially affect the Company’s ability to generate revenue. Recently Adopted Accounting Pronouncements In July 2015, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2015-11, Inventory: Simplifying the Measurement of Inventory In April 2016, the FASB issued ASU No. 2016-09, Share-Based Payment: Simplifying the Accounting for Share-Based Payments Recently Issued Accounting Pronouncements In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers In March 2016, the FASB issued ASU No. 2016-08, Revenue Recognition: Clarifying the new Revenue Standard’s Principal-Versus-Agent Guidance In April 2016, the FASB issued ASU No. 2016-10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing In May 2016, the FASB issued ASU No. 2016-12, Revenue from Contracts with Customers (Topic 606): Narrow Scope Improvements and Practical Expedients. The new revenue standard and the standards that amend it will be effective for public entities for fiscal years and interim periods within those fiscal years beginning after December 15, 2017, using either of the following transition methods: (i) a full retrospective approach reflecting the application of the standard in each prior reporting period with the option to elect certain practical expedients; or (ii) a retrospective approach with the cumulative effect of initially adopting ASU 2014-09 recognized at the date of adoption (which includes additional footnote disclosures). The Company is in the initial stages of evaluating the effect of adoption of ASU 2014-09 on its financial statements and continues to evaluate the available transition methods. The Company has begun assessing the standard for all of its contracts with customers, which includes performing a detailed review of how the new standard affects each of its different types of customer contracts and comparing historical accounting policies and practices to the new standard. The Company will continue its evaluation of the standards update through the date of adoption. In February 2016, the FASB issued ASU No. 2016-02, Leases In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments In May 2017, the FASB issued ASU No. 2017-09, Compensation – Stock Compensation (Topic 718): Scope of Modification Accounting

Inventory

Inventory	6 Months Ended
	Jun. 30, 2017
Inventory Disclosure [Abstract]
Inventory	Note 3. Inventory Inventory, net of allowance, consisted of the following as of the date indicated: June 30, December 31, 2017 2016 Raw materials $ 1,106,363 $ 1,222,437 Work in process 106 1,762 Finished goods 414,918 557,161 Total gross inventory 1,521,387 1,781,360 Less inventory allowance (207,880 ) (270,307 ) $ 1,313,507 $ 1,511,053 For the three and six months ended June 30, 2017, the Company recorded net decreases in the inventory reserve of $66,250 and $62,427, respectively, compared with net increases of $73,305 and $91,542, respectively, for the three and six months ended June 30, 2016, to adjust for estimated shrinkage and obsolescence. For the three and six months ended June 30, 2017, the Company recorded adjustments to provision for excess inventory of $51,599 and $244,026, respectively. For the three and six months ended June 30, 2016, the Company recorded adjustments to provision for excess inventory of $119,221 and $149,763, respectively. Adjustments in these periods to the allowance for estimated shrinkage, obsolescence and excess inventory were recognized within cost of revenue in the condensed statement of operations.

Fair Value Instruments

Fair Value Instruments	6 Months Ended
	Jun. 30, 2017
Fair Value Disclosures [Abstract]
Fair Value Instruments	Note 4. Fair Value Instruments The carrying value of financial instruments classified as current assets and current liabilities approximate fair value due to their liquidity and short-term nature. Investments that are classified as available-for-sale are recorded at fair value, which is determined using quoted market prices, broker dealer quotations, or alternative pricing sources with reasonable levels of price transparency. Financial assets and liabilities measured at fair value are classified in their entirety in the fair value hierarchy, based on the lowest level input significant to the fair value measurement. The following table classifies the Company’s financial assets and liabilities measured at fair value on a recurring basis at June 30, 2017 and December 31, 2016, respectively, in the fair value hierarchy: Balance at June 30, 2017 Level 1 Level 2 Level 3 Total Asset included in: Cash and cash equivalents Money market securities $ 12,434,936 $ — $ — $ 12,434,936 Total $ 12,434,936 $ — $ — $ 12,434,936 Balance at December 31, 2016 Level 1 Level 2 Level 3 Total Asset included in: Cash and cash equivalents Money market securities $ 6,443,102 $ — $ — $ 6,443,102 Investments available-for-sale at fair value U.S. government obligations $ 1,300,663 $ — $ — $ 1,300,663 Corporate debt securities $ — $ 3,004,238 $ — $ 3,004,238 Total $ 7,743,765 $ 3,004,238 $ — $ 10,748,003 There are no other financial instruments subject to fair value measurement on a recurring basis. Transfers to and from Levels 1, 2 and 3 are recognized at the end of the reporting period. There were no transfers between levels for the six months ended June 30, 2017 or for the year ended December 31, 2016. Level 1 instruments include U.S. Government money market funds and U.S. Treasuries. These instruments are valued using quoted market prices for identical unrestricted instruments in active markets. The Company defines active markets for debt instruments based on both the average daily trading volume and the number of days with trading activity. Level 2 instruments include corporate debt securities. Valuations of Level 2 instruments can be verified to quoted prices, recent trading activity for identical or similar instruments, broker or dealer quotations or alternative pricing sources with reasonable levels of price transparency. Consideration is given to the nature of the quotations (e.g., indicative or firm) and the relationship of recent market activity to the prices provided from alternative pricing sources. Fair values of these assets are based on prices provided by independent market participants that are based on observable inputs using market-based valuation techniques. These valuation models and analytical tools use market pricing or similar instruments that are both objective and publicly available, including matrix pricing or reported trades, benchmark yields, broker/dealer quotes, issuer spreads, two-sided markets, benchmark securities, bids and/or offers. The Company did not adjust any of the valuations received from these third parties with respect to any of its Level 1 or 2 securities for the periods ended June 30, 2017 or December 31, 2016.

Available for Sale Securities

Available for Sale Securities	6 Months Ended
	Jun. 30, 2017
Investments Debt And Equity Securities [Abstract]
Available for Sale Securities	Note 5. Available for Sale Securities The Company had no available-for-sale securities as of June 30, 2017. The following is a summary of the Company’s available-for-sale securities at December 31, 2016. December 31, 2016 Gross Gross Fair Value Amortized Unrealized Unrealized (Net Carrying Cost Gains Losses Amount) U.S. Treasury securities $ 1,300,151 $ 512 $ — $ 1,300,663 Corporate debt securities 3,005,840 — (1,602 ) 3,004,238 Total available-for-sale securities $ 4,305,991 $ 512 $ (1,602 ) $ 4,304,901 The net adjustment to unrealized holding gains on available-for-sale securities, net of tax in other comprehensive income totaled $736 and $1,090 for the three and six months ended June 30, 2017, respectively, and $4,522 and $43,873 for the three and six months ended June 30, 2016, respectively.

Property and Equipment

Property and Equipment	6 Months Ended
	Jun. 30, 2017
Property Plant And Equipment [Abstract]
Property and Equipment	Note 6. Property and Equipment Property and equipment, net, consists of the following: June 30, December 31, 2017 2016 Office equipment $ 505,221 $ 447,580 Leasehold improvements 1,854,052 1,847,378 Laboratory and manufacturing equipment 2,703,030 2,659,621 Field equipment 131,096 131,096 Software 150,451 150,451 Construction in progress 261,633 176,963 5,605,483 5,413,089 Less: accumulated depreciation and amortization (2,724,996 ) (2,142,892 ) $ 2,880,487 $ 3,270,197 Depreciation and leasehold improvement amortization expense was $291,421 and $587,466 for the three and six months ended June 30, 2017, respectively, and $371,805 and $728,828 for the three and six months ended June 30, 2016, respectively.

Accrued Liabilities

Accrued Liabilities	6 Months Ended
	Jun. 30, 2017
Accrued Liabilities Current [Abstract]
Accrued Liabilities	Note 7. Accrued Liabilities Accrued liabilities consist of the following: June 30, December 31, 2017 2016 Employee compensation and benefits $ 683,197 $ 1,088,773 Employee compensation for future absences 198,682 173,533 Interest 60,240 82,591 Professional fees 89,795 79,029 Other 181,697 246,360 $ 1,213,611 $ 1,670,286

Growth Term Loan

Growth Term Loan	6 Months Ended
	Jun. 30, 2017
Debt Disclosure [Abstract]
Growth Term Loan	Note 8. Growth Term Loan There have been no significant modifications to the terms and conditions of the Growth Term Loan since the disclosures made in the Company’s Annual Report on Form 10-K, filed with the SEC on March 23, 2017. The remaining principal repayments due under the Growth Term Loan as of June 30, 2017 are as follows for each fiscal year: 2017 $ 3,263,152 2018 5,163,822 Total Growth Term Loan payments 8,426,974 Less discount and deferred financing costs (150,049 ) Plus final fee premium 606,684 Total Growth Term Loan, net $ 8,883,609

Other Agreements

Other Agreements	6 Months Ended
	Jun. 30, 2017
Other Agreements [Abstract]
Other Agreements	Note 9. Other Agreements NuvoGen Obligation There have been no significant modifications to the terms and conditions of the Company’s NuvoGen obligation since the disclosures made in the Company’s Annual Report on Form 10-K, filed with the SEC on March 23, 2017. The minimum remaining payments due to NuvoGen at June 30, 2017 are as follows for each fiscal year, although actual payments could be significantly more than provided in the table in 2018 and beyond, to the extent that 6% of the Company’s revenue exceeds $400,000: 2017 $ 400,000 2018 400,000 2019 400,000 2020 400,000 2021 400,000 2022 and beyond 6,298,743 Total NuvoGen obligation payments 8,298,743 Less discount 22,741 Total NuvoGen obligation, net $ 8,321,484 Development Agreements Illumina, Inc. Agreement In June 2017, the Company entered into an Amended and Restated Development and Component Supply Agreement with Illumina, Inc. (“Illumina”), effective May 31, 2017 (the “Restated Agreement”), which amended and restated the parties’ IVD Test Development and Component Supply Agreement entered into in October 2014 (the “Original Agreement”). The Restated Agreement provides for the development and worldwide commercialization by the Company of nuclease-protection-based RNA or DNA profiling tests (“IVD test kits”) for use with Illumina’s MiSeqDx sequencer in the field of diagnostic oncology testing in humans (the “Field”). Under the Restated Agreement, the parties have agreed to continue activities under the first development plan which was entered into pursuant to the Original Agreement, and the Company may, at its discretion, submit additional development plans for IVD test kits in the Field to Illumina for its approval, not to be unreasonably withheld. Under each development plan, Illumina will provide specified regulatory support and rights, and develop and deliver to the Company an executable version of custom software, which, when deployed on Illumina’s MiSeqDx sequencer, would enable sequencing by the end-user of the subject IVD test kit probe library. Illumina retains ownership of the custom software, subject to the Company’s right to use the custom software in connection with the commercialization of IVD test kits. The Company is required to pay Illumina up to $0.6 million in the aggregate upon achievement of specified regulatory milestones relating to the IVD test kits. There have been no additional contractual milestones reached since the disclosures made by the Company in its Annual Report on Form 10-K, filed with the SEC on March 23, 2017. In addition, the Company has agreed to pay Illumina a single digit percentage royalty on net sales of any IVD test kits that the Company commercializes pursuant to the Restated Agreement. The Company has submitted one additional development plan for an IVD test kit to Illumina, resulting in a required payment to Illumina of $50,000 for the three and six months ended June 30, 2017, included in accounts payable in the condensed balance sheets as of June 30, 2017. Ongoing research and development costs for development plans under the Restated Agreement have been expensed as incurred. Absent earlier termination, the Restated Agreement will expire in May 2027; however, Illumina is no longer obligated to notify the Company of changes in its products that may affect the Company’s IVD test kits after May 31, 2023. The Company may terminate the Restated Agreement at any time upon 90 days’ written notice and may terminate any development plan under the Restated Agreement upon 30 days’ prior written notice. Illumina may terminate the Restated Agreement upon 30 days’ prior written notice if the Company undergoes certain changes of control, subject to a transition period of up to 12 months for then-ongoing development plans. Either party may terminate the Restated Agreement upon the other party’s material breach of the Restated Agreement that remains uncured for 30 days, or upon the other party’s bankruptcy. Other Development Agreements There have been no significant modifications or financial events relating to the development agreements entered into by the Company in prior periods with Invetech PTY Ltd. or Life Technologies Corporation since the disclosures made by the Company in its Annual Report on Form 10-K, filed with the SEC on March 23, 2017. Collaboration Agreements Merck KGaA Agreement The Company earned the first milestone-based payment under its Master CDx Agreement with Merck KGaA, Darmstadt, Germany (“Merck KGaA”) in the second quarter of 2017. Service revenue of Other Collaboration Agreements There have been no significant modifications or financial events relating to the previously disclosed collaboration agreement entered into by the Company with Bristol-Myers Squibb since disclosures made by the Company in its Annual Report on Form 10‑K, filed with the SEC on March 23, 2017. Other Agreements with Related Parties Refer to Note 14 for discussion of agreements with related parties.

Net Loss per Share

Net Loss per Share	6 Months Ended
	Jun. 30, 2017
Earnings Per Share [Abstract]
Net Loss per Share	Note 10. Net Loss Per Share Net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock or common stock equivalents outstanding. The numerator and the denominator used in computing both basic and diluted net loss per share for each period are the same. The following table provides the numerator and denominator used in computing basic and diluted net loss per share for the periods presented: Three Months Ended June 30, Six Months Ended June 30, 2017 2016 2017 2016 Numerator: Net loss $ (5,840,902 ) $ (6,851,603 ) $ (11,657,176 ) $ (13,878,027 ) Denominator: Weighted-average shares outstanding-basic and diluted 9,769,322 7,018,502 8,875,177 6,952,012 Net loss per share, basic and diluted $ (0.60 ) $ (0.98 ) $ (1.31 ) $ (2.00 ) The following outstanding options and warrants were excluded from the computation of diluted net loss per share for the periods presented because their effect would have been anti-dilutive: Six Months Ended June 30, 2017 2016 Options to purchase common stock 1,436,978 1,055,831 Common stock warrant 219,723 219,723 Restricted stock units 208,999 24,999

Stockholders Deficit

Stockholders Deficit	6 Months Ended
	Jun. 30, 2017
Equity [Abstract]
Stockholders' Deficit	Note 11. Stockholders’ Deficit Cantor Fitzgerald & Co. Market Offering In April 2017, the Company entered into a Controlled Equity Offering Sales Agreement (the “Sales Agreement”) with Cantor Fitzgerald & Co., as sales agent (“Cantor Fitzgerald”), pursuant to which the Company may offer and sell, from time to time, through Cantor Fitzgerald, shares of the Company’s common stock, par value $0.001 per share, by any method deemed to be an “at the market offering” as defined in Rule 415 under the Securities Act of 1933, as amended (the “ATM Offering”). In April 2017, the Company also filed a prospectus supplement (File No. 333-216977) with the SEC relating to the offer and sale of up to $20,000,000 of common stock in the ATM Offering. In June 2017, the Company filed an amendment to the prospectus supplement with the SEC to increase the amount of common stock that may be offered and sold in the ATM Offering under the Sales Agreement to $40,000,000 in the aggregate, inclusive of the common stock previously sold in the ATM Offering prior to the date of the amendment. As of June 30, 2017, the Company has sold 3,184,972 shares of common stock under the ATM Offering at then-market prices for total gross proceeds of approximately $15.4 million. After sales commissions and $0.2 million of other offering expenses paid and payable by the Company in connection with the ATM Offering, the Company’s aggregate net proceeds through June 30, 2017 were approximately $14.7 million. These costs have been recorded as a reduction of proceeds received in arriving at the amount recorded in additional paid-in capital as of June 30, 2017. Treasury Stock In January 2017, the Company’s board of directors approved the retirement of the 1,396 shares of the Company’s common stock previously held in treasury, and returned them to the status of authorized and unissued shares of the Company’s common stock. Stock-based Compensation As of June 30, 2017, there were 89,968 shares available for issuance under the Company’s 2014 Equity Incentive Plan (the “Plan”) and options to purchase 1,436,978 shares of common stock were outstanding, including 714,443 options that were fully vested. As of June 30, 2017, there was total unrecognized compensation expense of $1,010,315 related to unvested stock options, which the Company expects to recognize over a weighted-average period of approximately 1.93 years. A summary of the Plan’s stock option activity is as follows: Number of Shares Weighted- Average Exercise Price Per Share Weighted- Average Remaining Contractual Life (Years) Aggregate Intrinsic Value Balance at December 31, 2016 1,161,705 $ 3.35 7.7 $ 36,887 Granted 349,000 2.04 Exercised (40,809 ) 2.69 $ 152,071 Forfeited (30,057 ) 3.23 Expired/Cancelled (2,861 ) 9.03 Balance at June 30, 2017 1,436,978 $ 3.03 7.8 $ 538,789 Exercisable at June 30, 2017 714,443 $ 3.40 6.5 $ 214,339 As of June 30, 2017, there were 208,999 restricted stock units (“RSUs”) outstanding, including 10,000 vested and unissued RSUs and 198,999 unvested RSUs. Unrecognized compensation expense related to the remaining unvested RSUs was $173,737 at June 30, 2017, which the Company expects to recognize over a weighted-average remaining service period of 0.6 years. A summary of the Plan’s RSU activity is as follows: Restricted Stock Units (RSU) Weighted- Average Grant Date Fair Value Per Share Balance at December 31, 2016 355,499 $ 2.41 Granted 10,000 1.75 Exercised (154,000 ) 2.44 Forfeited (2,500 ) 2.46 Balance at June 30, 2017 208,999 $ 2.36 Stock-based compensation expense recorded in the condensed statements of operations for the three and six months ended June 30, 2017 and 2016 was as follows: Three Months Ended June 30, Six Months Ended June 30, 2017 2016 2017 2016 Selling, general and administrative $ 294,591 $ 112,043 $ 574,174 $ 233,593 Research and development 93,103 30,056 181,464 67,790 Cost of revenue 30,243 9,989 58,945 20,753 $ 417,937 $ 152,088 $ 814,583 $ 322,136

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2017
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 12. Commitments and Contingencies Legal Matters The Company’s industry is characterized by frequent claims and litigation, including claims regarding intellectual property and product liability. As a result, the Company may be subject to various legal proceedings from time to time. The results of any current or future litigation cannot be predicted with certainty, and regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources, and other factors. Any current litigation is considered immaterial and counter claims have been assessed as remote. Leases The Company leases office and laboratory space in Tucson, Arizona under two non-cancelable operating leases. There have been no changes to the Company’s office and laboratory space leases since the disclosures made by the Company in its Annual Report on Form 10-K, filed with the SEC on March 23, 2017. The Company’s remaining minimum real estate lease payments before common area maintenance charges for each fiscal year as of June 30, 2017 are as follows: 2017 $ 254,964 2018 512,533 2019 514,977 2020 517,457 2021 43,139 $ 1,843,070 As of June 30, 2017, the Company also has capital lease commitments consisting of approximately $115,000 of leases for computer equipment varying in length from 36 to 48 months and an equipment financing arrangement of approximately $13,000 with a vendor that expires in December 2017 that have not been included in the minimum lease payments schedule above. Product Warranty The following is a summary of the Company’s general product warranty reserve: Six Months Ended June 30, 2017 2016 Beginning balance $ 50,426 $ 20,213 Cost of warranty claims (4,296 ) (32,760 ) Increase (decrease) in warranty reserve (14,817 ) 49,024 Ending balance $ 31,313 $ 36,477 Warranty reserve is included in accrued liabilities in the condensed balance sheets as of June 30, 2017 and December 31, 2016. Expense relating to the recording of this reserve is recorded in cost of revenue within the condensed statements of operations.

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2017
Income Tax Disclosure [Abstract]
Income Taxes	Note 13. Income Taxes The Company provides for income taxes based upon management’s estimate of taxable income or loss for each respective period. The Company recognizes an asset or liability for the deferred tax consequences of temporary differences between the tax bases of assets and liabilities and their reported amounts in the financial statements. These temporary differences would result in deductible or taxable amounts in future years, when the reported amounts of the assets are recovered or liabilities are settled, respectively. In each period since inception, the Company has recorded a valuation allowance for the full amount of its net deferred tax assets, as it is not more likely than not that these will be realized. As a result, the Company has not recorded any federal or state income tax benefit in the condensed statements of operations; however, state income tax expense has been recorded for state minimum taxes. The Company periodically reviews its filing positions for all open tax years in all U.S. federal, state and international jurisdictions where the Company is or might be required to file tax returns or other required reports. The Company applies a two-step approach to recognizing and measuring uncertain tax positions. The Company evaluates the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained in a court of last resort. The term “more likely than not” means a likelihood of more than 50 percent. Otherwise, the Company may not recognize any of the potential tax benefit associated with the position. The Company recognizes a benefit for a tax position that meets the more likely than not criterion at the largest amount of tax benefit that is greater than 50 percent likely of being realized upon its effective resolution. Unrecognized tax benefits involve management’s judgment regarding the likelihood of the benefit being sustained. The final resolution of uncertain tax positions could result in adjustments to recorded amounts and may affect the Company’s results of operations, financial position and cash flows. The Company has not identified any uncertain tax positions at June 30, 2017 or December 31, 2016. The Company’s policy is to recognize interest and/or penalties related to income tax matters in income tax expense. The Company had no accrual for interest or penalties at June 30, 2017 and December 31, 2016, respectively, and has not recognized interest or penalties of significance during the six months ended June 30, 2017 and 2016, respectively, since there are no material unrecognized tax benefits. The Company has not made or had payments due for income taxes for the periods ended June 30, 2017 or December 31, 2016, other than state minimum taxes. Management believes no material change to the amount of unrecognized tax benefits will occur within the next 12 months. The Company has established a valuation allowance against the entire net deferred tax asset. A preliminary analysis of past and subsequent equity offerings by the Company, and other transactions that have an impact on the Company’s ownership structure, concluded that the Company may have experienced one or more ownership changes under Sections 382 and 383 of the Internal Revenue Code or IRC. Provisions of the IRC place special limitations on the usage of net operating losses and credits following an ownership change. Such limitations may limit or eliminate the potential future tax benefit to be realized by the Company from its accumulated net operating losses and research and development credits.

Related-Party Transactions

Related-Party Transactions	6 Months Ended
	Jun. 30, 2017
Related Party Transactions [Abstract]
Related-Party Transactions	Note 14. Related Party Transactions QIAGEN Agreement In June 2017, the Company entered into the first statement of work (“SOW One”) under its Master Assay Development, Commercialization and Manufacturing Agreement (“Governing Agreement”) with QIAGEN Manchester Limited (“QML”), a wholly owned subsidiary of QIAGEN, N.V. QIAGEN North American Holdings, Inc., a wholly owned subsidiary of QIAGEN N.V., is a greater than 5% holder of the Company’s outstanding common stock. SOW One addresses the initial activities of the Company and QML in support of the development and potential commercialization of a next generation sequencing-based companion diagnostic assay (the “PDP Assay”) that is the subject of a sponsor project agreement between QML and a biopharmaceutical company (“Pharma One”). The parties expect development activities for the PDP Assay to be the subject of more than one work plan under the sponsor project agreement and a corresponding number of statements of work under the Governing Agreement. The Company has determined that SOW One is a collaborative arrangement under ASC 808 and a multiple-element arrangement under ASC 605-25. After reviewing the deliverables under the arrangement, the Company concluded that all of the fixed and determinable contract consideration should be allocated to the development services to be performed by the Company. QML will pay the Company a monthly fee for development work performed by Company and its subcontractors (collectively, the “Monthly Fee”). The Monthly Fee is not contingent upon successful acceptance of project milestones by Pharma One; therefore, the Monthly Fee will be recognized as the respective payment amount becomes fixed or determinable and collectability from QML is reasonably assured. The Company and QML also will share any net profits resulting from performance of the development work as determined pursuant to the Governing Agreement. Such profit sharing payment(s) is deemed to be fixed or determinable upon completion of SOW One deliverables, acceptance of corresponding deliverables by Pharma One, and the calculation of net profit is mutually agreed by QML and the Company. Revenue of $277,400 has been included in service revenue in the condensed statements of operations for the three and six months ended June 30, 2017 relating to SOW One Monthly Fees, and in accounts receivables in the condensed balance sheets as of June 30, 2017, and no profit sharing payments have been received or recognized as of June 30, 2017. Costs relating to SOW One of $222,200 have been included in research and development expense in the condensed statements of operations for the three and six months ended June 30, 2017. No costs or revenue relating to SOW One were included in the condensed statements of operations for the three and six months ended June 30, 2016 as SOW One was not established until June 2017. SOW One will expire when all activities and deliverables have been completed by the respective responsible party and all payments from QML to the Company have been delivered, including any required profit sharing, unless terminated earlier in accordance with the terms of the Governing Agreement. Contemporaneous with entry into SOW One, the Governing Agreement was amended to provide that neither the Company nor QML may terminate SOW One or the Governing Agreement to the extent it relates to SOW One in the event of a change of control. Investor Rights Agreement Effective June 2, 2017, the Company agreed with Novo Holdings A/S, formerly known as Novo A/S, a greater than 5% holder of the Company’s outstanding common stock, that notwithstanding the termination provisions of the Amended and Restated Investor Rights Agreement (“IRA”) dated May 11, 2015 between the Company and certain stockholders named therein, Novo Holdings A/S would be entitled to demand registration rights set forth in the IRA until the earlier of (a) May 11, 2018 and (b) such time as all registrable securities held by the holder may be sold under Rule 144 during any 90-day period.

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2017
Subsequent Events [Abstract]
Subsequent Events	Note 15. Subsequent Events Notice of Potential Delisting from The NASDAQ Capital Market The Company’s common stock is currently listed on The NASDAQ Capital Market under the symbol “HTGM.” On July 31, 2017, the Company received notice from NASDAQ that the Company’s Market Value of Listed Securities (“MVLS”) did not satisfy The NASDAQ Capital Market continued listing requirements set forth in NASDAQ Stock Market Rule 5550(b)(2), nor does the Company satisfy alternative continued listing criteria under the stockholders’ equity or net income standards. The NASDAQ continued listing rules provide the Company a compliance period of 180 calendar days in which to regain compliance with the MVLS requirements. If at any time during this compliance period the Company’s MVLS closes at $35 million or more for a minimum of ten consecutive business days, the Company will regain compliance with NASDAQ’s continued listing requirements. In the event the Company does not regain compliance prior to the expiration of the compliance period, the Company’s common stock will be subject to delisting. There can be no assurance that the Company will be able to regain compliance with the MVLS requirement.

Basis of Presentation (Policies

Basis of Presentation (Policies)	6 Months Ended
	Jun. 30, 2017
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying interim unaudited condensed financial statements have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) and reflect the accounts of the Company as of June 30, 2017 and for the three and six months ended June 30, 2017 and 2016. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles in the United States of America (“GAAP”) for complete financial statements. The accompanying interim unaudited, condensed financial statements reflect all adjustments consisting of normal recurring adjustments which, in the opinion of management, are necessary for a fair statement of the Company’s financial position and the results of its operations and cash flows, as of and for the periods presented. The unaudited condensed balance sheet at December 31, 2016 has been derived from the audited financial statements at that date but does not include all of the information and disclosures required by GAAP for annual financial statements. The results of operations for the interim periods are not necessarily indicative of the results to be expected for the full year. These financial statements should be read in conjunction with the Company’s audited financial statements and notes thereto for the fiscal year ended December 31, 2016, included in the Company’s Annual Report on Form 10-K filed with the SEC on March 23, 2017.
Going Concern	Going Concern In accordance with the criteria of Accounting Standards Update (“ASU”) No. 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern The Company will need to raise additional capital to fund its operations until its revenue reaches a level sufficient to provide for self-sustaining cash flows. There can be no assurance that additional capital will be available on acceptable terms, or at all, or that the Company’s revenue will reach a level sufficient to provide for self-sustaining cash flows. If sufficient additional capital is not available as and when needed, the Company may have to delay, scale back or discontinue one or more product development programs, curtail its commercialization activities, significantly reduce expenses, sell assets (potentially at a discount to their fair value or carrying value), enter into relationships with third parties to develop or commercialize products or technologies that the Company otherwise would have sought to develop or commercialize independently, cease operations altogether, pursue a sale of the Company at a price that may result in up to a total loss on investment for its stockholders, file for bankruptcy or seek other protection from creditors, or liquidate all assets. In addition, if the Company defaults under its term loan agreement, its lenders could foreclose on its assets, including substantially all of its cash and cash equivalents which are held in accounts with its lenders.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. The Company’s significant estimates include revenue recognition, stock-based compensation expense, income tax valuation allowances, recovery of long-lived assets, inventory obsolescence and inventory valuation. Actual results could materially differ from those estimates.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The carrying value of financial instruments classified as current assets and current liabilities approximate fair value due to their liquidity and short-term nature. Investments that are classified as available-for-sale are recorded at fair value, which was determined using quoted market prices, broker or dealer quotations or alterative pricing sources with reasonable levels of transparency. The Growth Term Loan and NuvoGen obligation are considered financial instruments. However, the Company is unable to reasonably determine the fair value of these obligations.
Concentration Risks	Concentration Risks Financial instruments that potentially subject the Company to credit risk consist principally of cash and cash equivalents and uncollateralized accounts receivable. The Company maintains the majority of its cash balances in the form of cash deposits in bank checking and money market accounts in amounts in excess of federally insured limits. Management believes, based upon the quality of the financial institution, that the credit risk with regard to these deposits is not significant. The Company sells its instruments, consumables, sample processing services, custom panel design and development services primarily to biopharmaceutical companies, academic institutions and molecular labs. The Company routinely assesses the financial strength of its customers and credit losses have been minimal to date. The Company had product revenue consisting of revenue from the sale of instruments and consumables for the three and six months ended June 30, 2017 and 2016, as follows: Three Months Ended June 30, Six Months Ended June 30, 2017 2016 2017 2016 Instruments $ 148,479 $ 3,119 $ 171,058 $ 82,300 Consumables 258,698 574,008 777,263 1,095,017 Total product revenue $ 407,177 $ 577,127 $ 948,321 $ 1,177,317 The Company had service revenue consisting of revenue from custom assay development and sample processing for the three and six months ended June 30, 2017 and 2016, as follows: Three Months Ended June 30, Six Months Ended June 30, 2017 2016 2017 2016 Custom assay development $ 582,072 $ — $ 623,359 $ — Sample processing 469,096 1,318,689 1,257,834 1,583,731 Collaboration agreement 302,411 — 302,411 — Total service revenue $ 1,353,579 $ 1,318,689 $ 2,183,604 $ 1,583,731 The Company’s top three customers accounted for 16%, 15% and 13% of the Company’s total revenue for the three months ended June 30, 2017, compared with 60%, 11% and 5% for the three months ended June 30, 2016. The top three customers accounted for 16%, 12% and 9% of the Company’s revenue for the six months ended June 30, 2017, compared with 43%, 18% and 7% for the six months ended June 30, 2016. The top two customers accounted for approximately 13% and 12% of the Company’s accounts receivable as of June 30, 2017, compared with approximately 28% and 15% as of December 31, 2016. The Company currently relies on a single supplier to supply a subcomponent used in the HTG EdgeSeq processors and a second single supplier to provide raw materials used in its HTG EdgeSeq proprietary assays. A loss of either of these suppliers could significantly delay the delivery of products or the completion of services to be performed, which in turn would materially affect the Company’s ability to generate revenue.
Recently Adopted and Issued Accounting Pronouncements	Recently Adopted Accounting Pronouncements In July 2015, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2015-11, Inventory: Simplifying the Measurement of Inventory In April 2016, the FASB issued ASU No. 2016-09, Share-Based Payment: Simplifying the Accounting for Share-Based Payments Recently Issued Accounting Pronouncements In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers In March 2016, the FASB issued ASU No. 2016-08, Revenue Recognition: Clarifying the new Revenue Standard’s Principal-Versus-Agent Guidance In April 2016, the FASB issued ASU No. 2016-10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing In May 2016, the FASB issued ASU No. 2016-12, Revenue from Contracts with Customers (Topic 606): Narrow Scope Improvements and Practical Expedients. The new revenue standard and the standards that amend it will be effective for public entities for fiscal years and interim periods within those fiscal years beginning after December 15, 2017, using either of the following transition methods: (i) a full retrospective approach reflecting the application of the standard in each prior reporting period with the option to elect certain practical expedients; or (ii) a retrospective approach with the cumulative effect of initially adopting ASU 2014-09 recognized at the date of adoption (which includes additional footnote disclosures). The Company is in the initial stages of evaluating the effect of adoption of ASU 2014-09 on its financial statements and continues to evaluate the available transition methods. The Company has begun assessing the standard for all of its contracts with customers, which includes performing a detailed review of how the new standard affects each of its different types of customer contracts and comparing historical accounting policies and practices to the new standard. The Company will continue its evaluation of the standards update through the date of adoption. In February 2016, the FASB issued ASU No. 2016-02, Leases In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments In May 2017, the FASB issued ASU No. 2017-09, Compensation – Stock Compensation (Topic 718): Scope of Modification Accounting

Basis of Presentation (Tables)

Basis of Presentation (Tables)	6 Months Ended
	Jun. 30, 2017
Accounting Policies [Abstract]
Product Revenue from Sale of Instruments and Consumables and Service Revenue from Custom Assay Development and Sample Processing	The Company had product revenue consisting of revenue from the sale of instruments and consumables for the three and six months ended June 30, 2017 and 2016, as follows: Three Months Ended June 30, Six Months Ended June 30, 2017 2016 2017 2016 Instruments $ 148,479 $ 3,119 $ 171,058 $ 82,300 Consumables 258,698 574,008 777,263 1,095,017 Total product revenue $ 407,177 $ 577,127 $ 948,321 $ 1,177,317 The Company had service revenue consisting of revenue from custom assay development and sample processing for the three and six months ended June 30, 2017 and 2016, as follows: Three Months Ended June 30, Six Months Ended June 30, 2017 2016 2017 2016 Custom assay development $ 582,072 $ — $ 623,359 $ — Sample processing 469,096 1,318,689 1,257,834 1,583,731 Collaboration agreement 302,411 — 302,411 — Total service revenue $ 1,353,579 $ 1,318,689 $ 2,183,604 $ 1,583,731

Inventory (Tables)

Inventory (Tables)	6 Months Ended
	Jun. 30, 2017
Inventory Disclosure [Abstract]
Schedule of Inventory	Inventory, net of allowance, consisted of the following as of the date indicated: June 30, December 31, 2017 2016 Raw materials $ 1,106,363 $ 1,222,437 Work in process 106 1,762 Finished goods 414,918 557,161 Total gross inventory 1,521,387 1,781,360 Less inventory allowance (207,880 ) (270,307 ) $ 1,313,507 $ 1,511,053

Fair Value Instruments (Tables)

Fair Value Instruments (Tables)	6 Months Ended
	Jun. 30, 2017
Fair Value Disclosures [Abstract]
Financial Assets and Liabilities Measured at Fair Value on Recurring Basis	The following table classifies the Company’s financial assets and liabilities measured at fair value on a recurring basis at June 30, 2017 and December 31, 2016, respectively, in the fair value hierarchy: Balance at June 30, 2017 Level 1 Level 2 Level 3 Total Asset included in: Cash and cash equivalents Money market securities $ 12,434,936 $ — $ — $ 12,434,936 Total $ 12,434,936 $ — $ — $ 12,434,936 Balance at December 31, 2016 Level 1 Level 2 Level 3 Total Asset included in: Cash and cash equivalents Money market securities $ 6,443,102 $ — $ — $ 6,443,102 Investments available-for-sale at fair value U.S. government obligations $ 1,300,663 $ — $ — $ 1,300,663 Corporate debt securities $ — $ 3,004,238 $ — $ 3,004,238 Total $ 7,743,765 $ 3,004,238 $ — $ 10,748,003

Available for Sale Securities (

Available for Sale Securities (Tables)	6 Months Ended
	Jun. 30, 2017
Investments Debt And Equity Securities [Abstract]
Summary of Available-for-sale Securities	The Company had no available-for-sale securities as of June 30, 2017. The following is a summary of the Company’s available-for-sale securities at December 31, 2016. December 31, 2016 Gross Gross Fair Value Amortized Unrealized Unrealized (Net Carrying Cost Gains Losses Amount) U.S. Treasury securities $ 1,300,151 $ 512 $ — $ 1,300,663 Corporate debt securities 3,005,840 — (1,602 ) 3,004,238 Total available-for-sale securities $ 4,305,991 $ 512 $ (1,602 ) $ 4,304,901

Property and Equipment (Tables)

Property and Equipment (Tables)	6 Months Ended
	Jun. 30, 2017
Property Plant And Equipment [Abstract]
Summary of Property and Equipment	Property and equipment, net, consists of the following: June 30, December 31, 2017 2016 Office equipment $ 505,221 $ 447,580 Leasehold improvements 1,854,052 1,847,378 Laboratory and manufacturing equipment 2,703,030 2,659,621 Field equipment 131,096 131,096 Software 150,451 150,451 Construction in progress 261,633 176,963 5,605,483 5,413,089 Less: accumulated depreciation and amortization (2,724,996 ) (2,142,892 ) $ 2,880,487 $ 3,270,197

Accrued Liabilities (Tables)

Accrued Liabilities (Tables)	6 Months Ended
	Jun. 30, 2017
Accrued Liabilities Current [Abstract]
Summary of Accrued Liabilities	Accrued liabilities consist of the following: June 30, December 31, 2017 2016 Employee compensation and benefits $ 683,197 $ 1,088,773 Employee compensation for future absences 198,682 173,533 Interest 60,240 82,591 Professional fees 89,795 79,029 Other 181,697 246,360 $ 1,213,611 $ 1,670,286

Growth Term Loan (Tables)

Growth Term Loan (Tables)	6 Months Ended
	Jun. 30, 2017
Debt Disclosure [Abstract]
Principal Repayments Due Under Term Loan	2017 $ 3,263,152 2018 5,163,822 Total Growth Term Loan payments 8,426,974 Less discount and deferred financing costs (150,049 ) Plus final fee premium 606,684 Total Growth Term Loan, net $ 8,883,609

Other Agreements (Tables)

Other Agreements (Tables)	6 Months Ended
	Jun. 30, 2017
Commitments And Contingencies Disclosure [Abstract]
Schedule of Minimum Remaining Payments Due	2017 $ 400,000 2018 400,000 2019 400,000 2020 400,000 2021 400,000 2022 and beyond 6,298,743 Total NuvoGen obligation payments 8,298,743 Less discount 22,741 Total NuvoGen obligation, net $ 8,321,484

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	6 Months Ended
	Jun. 30, 2017
Earnings Per Share [Abstract]
Numerator and Denominator Used in Computing Basic and Diluted Net Loss per Share	The following table provides the numerator and denominator used in computing basic and diluted net loss per share for the periods presented: Three Months Ended June 30, Six Months Ended June 30, 2017 2016 2017 2016 Numerator: Net loss $ (5,840,902 ) $ (6,851,603 ) $ (11,657,176 ) $ (13,878,027 ) Denominator: Weighted-average shares outstanding-basic and diluted 9,769,322 7,018,502 8,875,177 6,952,012 Net loss per share, basic and diluted $ (0.60 ) $ (0.98 ) $ (1.31 ) $ (2.00 )
Outstanding Options and Warrants Excluded from Computation of Diluted Net Loss per Share	The following outstanding options and warrants were excluded from the computation of diluted net loss per share for the periods presented because their effect would have been anti-dilutive: Six Months Ended June 30, 2017 2016 Options to purchase common stock 1,436,978 1,055,831 Common stock warrant 219,723 219,723 Restricted stock units 208,999 24,999

Stockholders Deficit (Tables)

Stockholders Deficit (Tables)	6 Months Ended
	Jun. 30, 2017
Equity [Abstract]
Summary of Stock Option Plans Activity	A summary of the Plan’s stock option activity is as follows: Number of Shares Weighted- Average Exercise Price Per Share Weighted- Average Remaining Contractual Life (Years) Aggregate Intrinsic Value Balance at December 31, 2016 1,161,705 $ 3.35 7.7 $ 36,887 Granted 349,000 2.04 Exercised (40,809 ) 2.69 $ 152,071 Forfeited (30,057 ) 3.23 Expired/Cancelled (2,861 ) 9.03 Balance at June 30, 2017 1,436,978 $ 3.03 7.8 $ 538,789 Exercisable at June 30, 2017 714,443 $ 3.40 6.5 $ 214,339
Summary of RSU Plans Activity	A summary of the Plan’s RSU activity is as follows: Restricted Stock Units (RSU) Weighted- Average Grant Date Fair Value Per Share Balance at December 31, 2016 355,499 $ 2.41 Granted 10,000 1.75 Exercised (154,000 ) 2.44 Forfeited (2,500 ) 2.46 Balance at June 30, 2017 208,999 $ 2.36
Summary of Stock-Based Compensation	Stock-based compensation expense recorded in the condensed statements of operations for the three and six months ended June 30, 2017 and 2016 was as follows: Three Months Ended June 30, Six Months Ended June 30, 2017 2016 2017 2016 Selling, general and administrative $ 294,591 $ 112,043 $ 574,174 $ 233,593 Research and development 93,103 30,056 181,464 67,790 Cost of revenue 30,243 9,989 58,945 20,753 $ 417,937 $ 152,088 $ 814,583 $ 322,136

Commitments and Contingencies (

Commitments and Contingencies (Tables)	6 Months Ended
	Jun. 30, 2017
Commitments And Contingencies Disclosure [Abstract]
Minimum Real Estate Lease Payments Before Common Area Maintenance Charges	2017 $ 254,964 2018 512,533 2019 514,977 2020 517,457 2021 43,139 $ 1,843,070
Summary of Product Warranty Reserve	The following is a summary of the Company’s general product warranty reserve: Six Months Ended June 30, 2017 2016 Beginning balance $ 50,426 $ 20,213 Cost of warranty claims (4,296 ) (32,760 ) Increase (decrease) in warranty reserve (14,817 ) 49,024 Ending balance $ 31,313 $ 36,477

Description of Business - Addit

Description of Business - Additional Information (Details) - Segment	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Significant Accounting Policies [Line Items]
Number of operating segments			1
Sales Revenue, Net | Customer Concentration Risk | Customers Located Outside Of United States
Significant Accounting Policies [Line Items]
Sales revenue percentage	34.00%	10.00%	27.00%	10.00%

Basis of Presentation - Additio

Basis of Presentation - Additional Information (Details)	3 Months Ended		6 Months Ended		7 Months Ended	12 Months Ended
	Jun. 30, 2017USD ($)Customer	Jun. 30, 2016USD ($)Customer	Jun. 30, 2017USD ($)Customer	Jun. 30, 2016USD ($)Customer	Aug. 04, 2017USD ($)	Dec. 31, 2016USD ($)Customer	Dec. 31, 2015USD ($)
Significant Accounting Policies [Line Items]
Accumulated deficit	$ 127,263,220		$ 127,263,220			$ 115,606,044
Cash and cash equivalents	13,398,036	$ 7,510,493	13,398,036	$ 7,510,493		7,507,659	$ 3,293,983
Current liabilities	10,598,734		10,598,734			10,020,991
Long-term liabilities	$ 2,214,820		2,214,820			$ 5,389,137
Net proceeds from issuance of common stock			14,700,000
Maximum | Accounting Standards Update 2016-02 | Office and Equipment Leases
Significant Accounting Policies [Line Items]
Gross-up amount of leases effect in balance sheets			$ 3,000,000
Sales Revenue, Net | Customer Concentration Risk
Significant Accounting Policies [Line Items]
Number of customers | Customer	3	3	3	3
Sales Revenue, Net | Customer Concentration Risk | Customer One
Significant Accounting Policies [Line Items]
Sales revenue percentage	16.00%	60.00%	16.00%	43.00%
Sales Revenue, Net | Customer Concentration Risk | Customer Two
Significant Accounting Policies [Line Items]
Sales revenue percentage	15.00%	11.00%	12.00%	18.00%
Sales Revenue, Net | Customer Concentration Risk | Customer Three
Significant Accounting Policies [Line Items]
Sales revenue percentage	13.00%	5.00%	9.00%	7.00%
Accounts Receivable | Customer Concentration Risk
Significant Accounting Policies [Line Items]
Number of customers | Customer			2			2
Accounts Receivable | Customer Concentration Risk | Customer One
Significant Accounting Policies [Line Items]
Sales revenue percentage			13.00%			28.00%
Accounts Receivable | Customer Concentration Risk | Customer Two
Significant Accounting Policies [Line Items]
Sales revenue percentage			12.00%			15.00%
Subsequent Event
Significant Accounting Policies [Line Items]
Net proceeds from issuance of common stock					$ 14,900,000
NuvoGen
Significant Accounting Policies [Line Items]
Long-term liabilities	$ 10,600,000		$ 10,600,000

Basis of Presentation - Product

Basis of Presentation - Product Revenue from Sale of Instruments and Consumables (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Segment Reporting Revenue Reconciling Item [Line Items]
Total product revenue	$ 407,177	$ 577,127	$ 948,321	$ 1,177,317
Instruments
Segment Reporting Revenue Reconciling Item [Line Items]
Total product revenue	148,479	3,119	171,058	82,300
Consumables
Segment Reporting Revenue Reconciling Item [Line Items]
Total product revenue	$ 258,698	$ 574,008	$ 777,263	$ 1,095,017

Basis of Presentation - Service

Basis of Presentation - Service Revenue from Custom Assay Development and Sample Processing (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Segment Reporting Revenue Reconciling Item [Line Items]
Service	$ 1,353,579	$ 1,318,689	$ 2,183,604	$ 1,583,731
Custom assay development
Segment Reporting Revenue Reconciling Item [Line Items]
Service	582,072		623,359
Sample processing
Segment Reporting Revenue Reconciling Item [Line Items]
Service	469,096	$ 1,318,689	1,257,834	$ 1,583,731
Collaboration agreement
Segment Reporting Revenue Reconciling Item [Line Items]
Service	$ 302,411		$ 302,411

Inventory - Schedule of Invento

Inventory - Schedule of Inventory (Details) - USD ($)	Jun. 30, 2017	Dec. 31, 2016
Inventory Disclosure [Abstract]
Raw materials	$ 1,106,363	$ 1,222,437
Work in process	106	1,762
Finished goods	414,918	557,161
Total gross inventory	1,521,387	1,781,360
Less inventory allowance	(207,880)	(270,307)
Inventory, net	$ 1,313,507	$ 1,511,053

Inventory - Additional Informat

Inventory - Additional Information (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Inventory Disclosure [Abstract]
Net change in inventory valuation reserves	$ (66,250)	$ 73,305	$ (62,427)	$ 91,542
Provision for excess inventory	$ 51,599	$ 119,221	$ 244,026	$ 149,763

Fair Value Instruments - Financ

Fair Value Instruments - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - Fair Value, Measurements, Recurring - USD ($)	Jun. 30, 2017	Dec. 31, 2016
Asset included in:
Financial Assets	$ 12,434,936	$ 10,748,003
Cash and Cash Equivalents | Money Market Securities
Asset included in:
Financial Assets	12,434,936	6,443,102
Investments Available-for-sale at Fair Value | U.S. Government Obligations
Asset included in:
Financial Assets		1,300,663
Investments Available-for-sale at Fair Value | Corporate Debt Securities
Asset included in:
Financial Assets		3,004,238
Level 1
Asset included in:
Financial Assets	12,434,936	7,743,765
Level 1 | Cash and Cash Equivalents | Money Market Securities
Asset included in:
Financial Assets	$ 12,434,936	6,443,102
Level 1 | Investments Available-for-sale at Fair Value | U.S. Government Obligations
Asset included in:
Financial Assets		1,300,663
Level 2
Asset included in:
Financial Assets		3,004,238
Level 2 | Investments Available-for-sale at Fair Value | Corporate Debt Securities
Asset included in:
Financial Assets		$ 3,004,238

Fair Value Instruments - Additi

Fair Value Instruments - Additional Information (Details) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2017	Dec. 31, 2016
Fair Value Disclosures [Abstract]
Fair value assets, Level 1 to Level 2 transfers, Amount	$ 0	$ 0
Fair value, assets, Level 2 to Level 1 transfers, Amount	0	0
Fair value, liabilities, Level 1 to Level 2 transfers, Amount	0	0
Fair value, liabilities, Level 2 to Level 1 transfers, Amount	0	0
Fair value, measurement with unobservable inputs reconciliation, recurring basis, asset transfers into Level 3	0	0
Fair value, measurement with unobservable inputs reconciliation, recurring Basis, asset, transfers out of Level 3	0	0
Fair Value, measurement with unobservable inputs reconciliation, liability, transfers into Level 3	0	0
Fair Value, measurement with unobservable inputs reconciliation, liability, transfers out of Level 3	$ 0	$ 0

Available for Sale Securities -

Available for Sale Securities - Additional Information (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016
Investments Debt And Equity Securities [Abstract]
Available for sale securities	$ 0		$ 0		$ 4,304,901
Net unrealized holding gains	$ 736	$ 4,522	$ 1,090	$ 43,873

Available for Sale Securities45

Available for Sale Securities - Summary of Available-for-sale Securities (Details) - USD ($)	Jun. 30, 2017	Dec. 31, 2016
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost		$ 4,305,991
Gross Unrealized Gains		512
Gross Unrealized Losses		(1,602)
Fair Value (Net Carrying Amount)	$ 0	4,304,901
U.S. Treasury Securities
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost		1,300,151
Gross Unrealized Gains		512
Fair Value (Net Carrying Amount)		1,300,663
Corporate Debt Securities
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost		3,005,840
Gross Unrealized Losses		(1,602)
Fair Value (Net Carrying Amount)		$ 3,004,238

Summary Of Property and Equipme

Summary Of Property and Equipment (Details) - USD ($)	Jun. 30, 2017	Dec. 31, 2016
Property Plant And Equipment [Abstract]
Office equipment	$ 505,221	$ 447,580
Leasehold improvements	1,854,052	1,847,378
Laboratory and manufacturing equipment	2,703,030	2,659,621
Field equipment	131,096	131,096
Software	150,451	150,451
Construction in progress	261,633	176,963
Total property and equipment, gross	5,605,483	5,413,089
Less: accumulated depreciation and amortization	(2,724,996)	(2,142,892)
Property and equipment, net	$ 2,880,487	$ 3,270,197

Property and Equipment - Additi

Property and Equipment - Additional Information (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Property Plant And Equipment [Abstract]
Depreciation and leasehold improvement amortization expense	$ 291,421	$ 371,805	$ 587,466	$ 728,828

Summary of Accrued Liabilities

Summary of Accrued Liabilities (Details) - USD ($)	Jun. 30, 2017	Dec. 31, 2016
Payables And Accruals [Abstract]
Employee compensation and benefits	$ 683,197	$ 1,088,773
Employee compensation for future absences	198,682	173,533
Interest	60,240	82,591
Professional fees	89,795	79,029
Other	181,697	246,360
Total accrued liabilities	$ 1,213,611	$ 1,670,286

Growth Term Loan - Principal Re

Growth Term Loan - Principal Repayments Due Under Term Loan (Details) - Term Loan	Jun. 30, 2017USD ($)
Debt Instrument [Line Items]
2,017	$ 3,263,152
2,018	5,163,822
Total Growth Term Loan payments	8,426,974
Less discount and deferred financing costs	(150,049)
Plus final fee premium	606,684
Total Growth Term Loan, net	$ 8,883,609

Other Agreements - Additional I

Other Agreements - Additional Information (Details) - USD ($)	1 Months Ended	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016
Other Agreements [Line Items]
Percentage on annual revenues for cash consideration to be paid		6.00%
Research and development		$ 1,618,889	$ 2,611,591	$ 2,885,952	$ 4,605,692
Agreement expiration date				May 31, 2027
Description on termination of agreement				The Company may terminate the Restated Agreement at any time upon 90 days’ written notice and may terminate any development plan under the Restated Agreement upon 30 days’ prior written notice. Illumina may terminate the Restated Agreement upon 30 days’ prior written notice if the Company undergoes certain changes of control, subject to a transition period of up to 12 months for then-ongoing development plans. Either party may terminate the Restated Agreement upon the other party’s material breach of the Restated Agreement that remains uncured for 30 days, or upon the other party’s bankruptcy.
Service revenue for research and development services		1,353,579	$ 1,318,689	$ 2,183,604	$ 1,583,731
Merck KGaA Agreement
Other Agreements [Line Items]
Service revenue for research and development services		25,000		25,000
Illumina, Inc. Agreement
Other Agreements [Line Items]
Aggregate payment upon achievement of specified regulatory milestones	$ 600,000	600,000		600,000
Additional contractual milestons payment						$ 0
Research and development		50,000		50,000
Agreement termination notice period	90 days
Development plan agreement termination notice period	30 days
Number of days material breach remains uncured	30 days
Minimum | NuvoGen Asset Purchase Agreement
Other Agreements [Line Items]
Asset purchase agreement quarterly installments due from beginning 2018	$ 400,000	$ 400,000		$ 400,000

Other Agreements - Schedule of

Other Agreements - Schedule of Minimum Remaining Payments Due (Details) - NuvoGen Asset Purchase Agreement	Jun. 30, 2017USD ($)
Purchase Obligation Fiscal Year Maturity [Line Items]
2,017	$ 400,000
2,018	400,000
2,019	400,000
2,020	400,000
2,021	400,000
2022 and beyond	6,298,743
Total NuvoGen obligation payments	8,298,743
Less discount	22,741
Total NuvoGen obligation, net	$ 8,321,484

Net Loss per Share - Numerator

Net Loss per Share - Numerator and Denominator Used in Computing Basic and Diluted Net Loss per Share (Detail) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Numerator:
Net loss	$ (5,840,902)	$ (6,851,603)	$ (11,657,176)	$ (13,878,027)
Denominator:
Weighted-average shares outstanding-basic and diluted	9,769,322	7,018,502	8,875,177	6,952,012
Net loss per share, basic and diluted	$ (0.60)	$ (0.98)	$ (1.31)	$ (2)

Net Loss per Share - Outstandin

Net Loss per Share - Outstanding Options, Warrants and Restricted Stock Units Excluded from Computation of Diluted Net Loss per Share (Detail) - shares	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Options to purchase common stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of diluted net loss per share	1,436,978	1,055,831
Restricted Stock Units R S U
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of diluted net loss per share	208,999	24,999
Warrant | Common Stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of diluted net loss per share	219,723	219,723

Stockholders Deficit - Addition

Stockholders Deficit - Additional Information (Details) - USD ($)	Jun. 30, 2017	Apr. 30, 2017	Jan. 31, 2017	Jun. 30, 2017	Aug. 04, 2017	Dec. 31, 2016
Class Of Stock [Line Items]
Issuance of common stock from the ATM Offering, Shares				3,184,972
Gross proceeds from issuance of common stock				$ 15,400,000
Other offering expenses paid and payable				200,000
Net proceeds from issuance of common stock				$ 14,700,000
Employee Stock Option
Class Of Stock [Line Items]
Options to purchase common stock outstanding	1,436,978			1,436,978		1,161,705
Restricted Stock Units R S U
Class Of Stock [Line Items]
Unrecognized compensation expense	$ 173,737			$ 173,737
Compensation expense period expected to be recognized				7 months 6 days
Number of shares unvested and outstanding	208,999			208,999	208,999	355,499
Number of shares vested and unissued				10,000
Number of shares unvested				198,999
Two Thousand Fourteen Equity Incentive Plan
Class Of Stock [Line Items]
Number of shares available for issuance	89,968			89,968
Options to purchase common stock outstanding	1,436,978			1,436,978
Options fully vested				714,443
Two Thousand Fourteen Equity Incentive Plan | Employee Stock Option
Class Of Stock [Line Items]
Unrecognized compensation expense	$ 1,010,315			$ 1,010,315
Compensation expense period expected to be recognized				1 year 11 months 5 days
Board Of Directors
Class Of Stock [Line Items]
Retirement of treasury stock, shares			1,396
Sales Agreement
Class Of Stock [Line Items]
Common stock selling price per share		$ 0.001
Common stock aggregate offering price	$ 40,000,000	$ 20,000,000

Stockholders Deficit - Summary

Stockholders Deficit - Summary of Stock Option Plans Activity (Details) - Employee Stock Option - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2017	Dec. 31, 2016
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Shares, Beginning Balance	1,161,705
Number of Shares, Granted	349,000
Number of Shares, Exercised	(40,809)
Number of Shares, Forfeited	(30,057)
Number of Shares, Expired/Cancelled	(2,861)
Number of Shares, Ending Balance	1,436,978	1,161,705
Number of Shares, Exercisable	714,443
Weighted-Average Exercise Price Per Share, Beginning Balance	$ 3.35
Weighted-Average Exercise Price Per Share, Granted	2.04
Weighted-Average Exercise Price Per Share, Exercised	2.69
Weighted-Average Exercise Price Per Share, Forfeited	3.23
Weighted-Average Exercise Price Per Share, Expired/Cancelled	9.03
Weighted-Average Exercise Price Per Share, Ending Balance	3.03	$ 3.35
Weighted-Average Exercise Price Per Share, Exercisable	$ 3.40
Weighted-Average Remaining Contractual Life, Outstanding	7 years 10 months 24 days	7 years 8 months 12 days
Weighted-Average Remaining Contractual Life, Exercisable	6 years 6 months
Aggregate Intrinsic Value, Balance	$ 538,789	$ 36,887
Aggregate Intrinsic Value, Exercised	152,071
Aggregate Intrinsic Value, Exercisable	$ 214,339

Stockholders Deficit - Summar56

Stockholders Deficit - Summary of RSU Plans Activity (Details) - Restricted Stock Units R S U	6 Months Ended
	Jun. 30, 2017$ / sharesshares
Restricted Stock Units (RSU)
Balance at December 31, 2016 | shares	355,499
Granted | shares	10,000
Exercised | shares	(154,000)
Forfeited | shares	(2,500)
Balance at June 30, 2017 | shares	208,999
Weighted Average Grant Date Fair Value Per Share
Balance at December 31, 2016 | $ / shares	$ 2.41
Granted | $ / shares	1.75
Exercised | $ / shares	2.44
Forfeited | $ / shares	2.46
Balance at June 30, 2017 | $ / shares	$ 2.36

Stockholders Deficit - Summar57

Stockholders Deficit - Summary of Stock-Based Compensation (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation	$ 417,937	$ 152,088	$ 814,583	$ 322,136
Selling, General and Administrative
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation	294,591	112,043	574,174	233,593
Research and Development
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation	93,103	30,056	181,464	67,790
Cost of Revenue
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation	$ 30,243	$ 9,989	$ 58,945	$ 20,753

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Details)	6 Months Ended
	Jun. 30, 2017USD ($)
Commitments And Contingencies [Line Items]
Lease expiration term	The Company leases office and laboratory space in Tucson, Arizona under two non-cancelable operating leases.
Lease equipment financing arrangement	$ 13,000
Lease expiration date of lease payments not in schedule	2017-12
Computer Equipment
Commitments And Contingencies [Line Items]
Capital lease commitments	$ 115,000
Computer Equipment | Minimum
Commitments And Contingencies [Line Items]
Capital lease commitment period	36 months
Computer Equipment | Maximum
Commitments And Contingencies [Line Items]
Capital lease commitment period	48 months

Commitments and Contingencies59

Commitments and Contingencies - Minimum Real Estate Lease Payments Before Common Area Maintenance Charges (Details)	Jun. 30, 2017USD ($)
Commitments And Contingencies Disclosure [Abstract]
2,017	$ 254,964
2,018	512,533
2,019	514,977
2,020	517,457
2,021	43,139
Total minimum lease payments	$ 1,843,070

Commitments and Contingencies60

Commitments and Contingencies - Schedule Of Product Warranty Reserve (Details) - USD ($)	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Commitments And Contingencies Disclosure [Abstract]
Beginning balance	$ 50,426	$ 20,213
Cost of warranty claims	(4,296)	(32,760)
Increase (decrease) in warranty reserve	(14,817)	49,024
Ending balance	$ 31,313	$ 36,477

Income Taxes - Additional Infor

Income Taxes - Additional Information (Details) - USD ($)	6 Months Ended		12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Income tax examination, likelihood of unfavorable settlement	greater than 50 percent
Uncertain tax positions	$ 0		$ 0
Accrued interest or penalties	0		0
Recognized interest or penalties	0	$ 0
Income taxes paid other than state minimum taxes	$ 0		$ 0

Related-Party Transactions - Ad

Related-Party Transactions - Additional Information (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Related Party Transaction [Line Items]
Service	$ 1,353,579	$ 1,318,689	$ 2,183,604	$ 1,583,731
Research and development	1,618,889	2,611,591	2,885,952	4,605,692
Revenues	1,760,756	1,895,816	3,131,925	2,761,048
SOW One
Related Party Transaction [Line Items]
Service	277,400		277,400
Profit sharing payments received or recongnized			0
Research and development	$ 222,200		$ 222,200
Costs		0		0
Revenues		$ 0		$ 0
Minimum | Novo Holdings A/S
Related Party Transaction [Line Items]
Beneficial ownership percentage held	5.00%		5.00%
QIAGEN North American Holdings, Inc. | Minimum
Related Party Transaction [Line Items]
Beneficial ownership percentage held	5.00%		5.00%

Subsequent Events - Additional

Subsequent Events - Additional Information (Details) $ in Millions	Jul. 31, 2017USD ($)
Subsequent Event
Subsequent Event [Line Items]
Market value of listed securities closing amount for a minimum of ten consecutive	$ 35